Zhejiang Garden Biopharmaceutical Co., Ltd.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable decline in its stock, dropping significantly today and over the past week and month. The company reported a net sales decrease and has faced challenges in the market, contrasting with the broader performance of the China Shanghai Composite index.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable decline in its stock price today, contrasting with the broader market's performance. Over the past week and month, the stock has experienced significant losses, and financial metrics indicate challenges, including a decline in net sales and a relatively high valuation.

Zhejiang Garden Biopharmaceutical Co., Ltd. faced a challenging trading day, with its stock declining significantly. Over the past week, the stock has dropped sharply, contrasting with broader market trends. The company reported a notable profit decrease and a decline in net sales, reflecting ongoing financial difficulties amid a complex market environment.

Zhejiang Garden Biopharmaceutical Co., Ltd. has seen notable stock performance, with significant gains over various timeframes. Despite impressive short-term growth, the company faces challenges in long-term metrics, including modest annual increases in net sales and operating profit. The current market capitalization is CNY 5,774 million.

Zhejiang Garden Biopharmaceutical Co., Ltd. experienced notable stock volatility, hitting an intraday low while contrasting with the Shanghai Composite's gains. Despite a strong year-to-date performance and significant annual growth, the company faces challenges, including a decline in profits and a relatively high valuation.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable rise in its stock price on June 17, 2026, outperforming the China Shanghai Composite. Over the past week and month, the company has demonstrated substantial growth, although long-term metrics indicate challenges in net sales and operating profit. Its market capitalization stands at CNY 5,774 million.

Zhejiang Garden Biopharmaceutical Co., Ltd. has seen significant stock performance, with a notable increase on June 16, 2026. Over the past week, the stock has outperformed the broader market. Despite recent gains, the company has faced challenges, including a decline in profits and fluctuating performance indicators.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with a slight decline in the broader market. Despite recent gains, the company has faced challenges, including a decline in annual profits and a relatively high price-to-book ratio, reflecting its competitive position in the sector.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with a decline in the broader market. Despite this uptick, the company has struggled over the past year, underperforming the China Shanghai Composite, and currently holds a mid-cap market capitalization in the pharmaceuticals sector.

Zhejiang Garden Biopharmaceutical Co., Ltd. faced a significant stock decline, with shares dropping 5.02% on March 23, 2026. Over the past week and month, the stock has decreased by 16.06% and 21.09%, respectively, while its annual performance shows a 9.26% decline, contrasting with the broader market trends.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market. Over the past week and month, the stock has experienced significant losses. Annual performance shows an 8.12% decline, while the company maintains a mid-cap status with key financial metrics indicating challenges in the sector.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. The company has struggled recently, with significant decreases over the past week and month. Its annual return remains low compared to the market, highlighting ongoing challenges in the competitive pharmaceuticals sector.

Zhejiang Garden Biopharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite a strong operating cash flow and net sales growth for the year, the company has underperformed over the past three years, reflecting mixed financial indicators.

Zhejiang Garden Biopharmaceutical Co., Ltd. has recently experienced a change in its overall evaluation, influenced by adjustments in valuation and quality metrics. The company shows a fair valuation with manageable debt levels, while its operational performance has led to a reassessment of its quality score.